Clinical proof-of-principle of the determination of the beta cell mass in vivo by SPECT imaging with the 111In-labeled GLP-1 analogue DTPA-[K40]-Exendin 4

Next Previous
Trial Profile

Clinical proof-of-principle of the determination of the beta cell mass in vivo by SPECT imaging with the 111In-labeled GLP-1 analogue DTPA-[K40]-Exendin 4

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2014

At a glance

  • Drugs Exenatide (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms GLP-1-CPOP

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
    • 06 Aug 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top